Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai's Brii Bio Invests in Artizan; Gains China Rights to Microbiota Treatment for IBD

publication date: Jun 11, 2019

Shanghai's Brii Bioscience will have China rights to as many as three infectious disease candidates developed by Artizan Biosciences, a spin-out from Yale University. Brii participated in a Series A funding that brought Artizan's total funds raised to $12 million, though Brii's financial commitment to the round was not disclosed. Artizan is developing intestinal microbiota candidates for inflammatory diseases including its lead candidate, a treatment for Inflammatory Bowel Disease (IBD). Artizan uses its IgA-SEQ™ technology platform to identify disease-driving bacteria contained in human intestinal microbiota. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital